Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-CRM Antibody Persistence and Booster Study
NCT00856297Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2009
- Primary completion
- Nov 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal meningitis (5 arms), sponsored by Novartis. Primary endpoint: Percentages of Subjects With Human Complement Serum Bactericidal Activity (hSBA) Titers >= 1:8 at 5 years. Started Feb 2009; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT00856297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856297.